AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

"We are thrilled to have been selected by AMED to participate in its program to strengthen the Japan Pharmaceutical Startup Ecosystem. Lymphomas and leukemias remain an area of high unmet medical need in all parts of the world, including Japan, and we are delighted to collaborate directly with many key opinion leaders and a broad set of stakeholders in this region to bring forward a truly paradigm-shifting therapeutic with meaningful benefit to patients" said Andrew Schiermeier, Ph.D., President & CEO of AvenCell Therapeutics.

TOKYO, 30/06/2025 (informazione.news - comunicati stampa - salute e benessere)

"We are thrilled to have been selected by AMED to participate in its program to strengthen the Japan Pharmaceutical Startup Ecosystem. Lymphomas and leukemias remain an area of high unmet medical need in all parts of the world, including Japan , and we are delighted to collaborate directly with many key opinion leaders and a broad set of stakeholders in this region to bring forward a truly paradigm-shifting therapeutic with meaningful benefit to patients" said Andrew Schiermeier , Ph.D., President & CEO of AvenCell Therapeutics.

For more information, please visit www.avencell.com

Contact: press@avencell.com

Logo - https://mma.prnewswire.com/media/2721944/AvenCell_Therapeutics_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/avencell-awarded-up-to-40-million-amed-grant-to-advance-allogeneic-car-t-program-302494507.html